Loading...
Loading...
SAN DIEGO--(BUSINESS WIRE)--
Ligand Pharmaceuticals Incorporated
LGND partner
GlaxoSmithKline plc
GSKGSK announced today that the
European Commission has granted an additional indication for Revolade™
(eltrombopag) as a treatment for low platelet counts (thrombocytopenia)
in adult patients with chronic hepatitis C infection, where the degree
of thrombocytopenia is the main factor preventing the initiation or
limiting the ability to maintain optimal interferon (IFN)-based therapy.1
Thrombocytopenia may prevent the initiation2 and maintenance
of peginterferon (pIFN)-based treatment, thereby reducing a patient's
chances of achieving a sustained virologic response (SVR)*3 -
the primary goal of hepatitis C treatment.
“We are extremely pleased with the decision of the European Commission,
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in